Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
Cancers
|
July 24, 2021
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
Katharina Kessel, Christof Bernemann, Martin Bögemann, et al.
Breast Care (Basel, Switzerland)
|
February 20, 2014
Genomic profiling in triple-negative breast cancer
Cornelia Liedtke, Christof Bernemann, Ludwig Kiesel, et al.
Annals of Translational Medicine
|
February 5, 2020
Considerations for AR-V7 testing in clinical routine practice
Christof Bernemann, Laura-Maria Krabbe, Andres Jan Schrader
World Journal of Urology
|
March 1, 2017
Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems
Christof Bernemann, Julie Steinestel, Martin Boegemann, et al.
Oncology Research and Treatment
|
April 3, 2017
[Not Available]
Christof Bernemann, Martin Bögemann, Julie Steinestel, et al.
European Urology
|
September 21, 2016
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
July 10, 2017
Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
September 20, 2016
Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
Maturitas
|
January 2, 2018
Reverse engineering of triple-negative breast cancer cells for targeted treatment
Lena Bluemel, Marie-Kristin von Wahlde, Joke Tio, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|
October 31, 2014
The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling
Marie-Kristin von Wahlde, Carolin Hülsewig, Christian Ruckert, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
Cancers
|
July 24, 2021
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
Katharina Kessel, Christof Bernemann, Martin Bögemann, et al.
Breast Care (Basel, Switzerland)
|
February 20, 2014
Genomic profiling in triple-negative breast cancer
Cornelia Liedtke, Christof Bernemann, Ludwig Kiesel, et al.
Annals of Translational Medicine
|
February 5, 2020
Considerations for AR-V7 testing in clinical routine practice
Christof Bernemann, Laura-Maria Krabbe, Andres Jan Schrader
World Journal of Urology
|
March 1, 2017
Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems
Christof Bernemann, Julie Steinestel, Martin Boegemann, et al.
Oncology Research and Treatment
|
April 3, 2017
[Not Available]
Christof Bernemann, Martin Bögemann, Julie Steinestel, et al.
European Urology
|
September 21, 2016
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
July 10, 2017
Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
European Urology
|
September 20, 2016
Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict
Julie Steinestel, Christof Bernemann, Andres J Schrader, et al.
Maturitas
|
January 2, 2018
Reverse engineering of triple-negative breast cancer cells for targeted treatment
Lena Bluemel, Marie-Kristin von Wahlde, Joke Tio, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|
October 31, 2014
The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling
Marie-Kristin von Wahlde, Carolin Hülsewig, Christian Ruckert, et al.
Page
of 5